This book investigates the role of pharmacogenomics in enhancing immunotherapy treatments. It explores genetic factors that influence patient responses to immune checkpoint inhibitors, CAR-T therapies, and vaccines. The text emphasizes personalized approaches to improve efficacy and reduce immune-related adverse effects. Aimed at oncologists and immunogenomic researchers, it advances the integration of genetics in immunotherapeutic strategies.
Justin Cooper integrates pharmacogenomics with immunotherapy to personalize treatments for dermatological cancers like melanoma. His research explores genetic markers that predict patient responses to immunotherapeutic agents, enhancing treatment efficacy and safety. Justin has authored numerous studies on optimizing immunotherapy regimens through pharmacogenomic insights. He also offers guidelines for clinicians to incorporate pharmacogenomic strategies into immunotherapy protocols, promoting personalized and effective cancer treatments in dermatology through genetic-informed approaches.